Qidong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qidong Li has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Boyi Gan
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
27 shared publications - Chao Mao
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
23 shared publications - Yuelong Yan
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
23 shared publications - Guang Lei
Furong Laboratory, Central South University, Changsha, China
22 shared publications - Li Zhuang
The University of Texas MD Anderson Cancer Center 1 Department of Experimental Radiation Oncology Houston, Texas
22 shared publications - Mingchuang Sun
The University of Texas MD Anderson Cancer Center 1 Department of Experimental Radiation Oncology Houston, Texas
22 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Primer sequences used for gene expression analyses
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Primer sequences used for gene expression analyses
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Representative images of immunohistochemical staining for Ki-67 in tumor tissues across the indicated treatment groups
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Representative images of immunohistochemical staining for Ki-67 in tumor tissues across the indicated treatment groups
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Body weight measurements of mice during treatment, indicating tolerability of the indicated therapeutic regimens
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Body weight measurements of mice during treatment, indicating tolerability of the indicated therapeutic regimens
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Genetic or pharmacologic inhibition of DHODH, in combination with IFN-γ treatment, enhances radiosensitivity in lung cancer cells, as determined by cell viability and clonogenic survival assays
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Genetic or pharmacologic inhibition of DHODH, in combination with IFN-γ treatment, enhances radiosensitivity in lung cancer cells, as determined by cell viability and clonogenic survival assays
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Quantification of immunohistochemical staining signals, including 4-HNE, Ki-67, and cleaved caspase-3, in tumor tissues from the indicated treatment groups
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Quantification of immunohistochemical staining signals, including 4-HNE, Ki-67, and cleaved caspase-3, in tumor tissues from the indicated treatment groups
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
CREB1 and CREB2 expression levels are positively associated with DHODH expression following radiotherapy, based on correlation analyses of gene expression data
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
CREB1 and CREB2 expression levels are positively associated with DHODH expression following radiotherapy, based on correlation analyses of gene expression data
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Radiation increases DHODH expression and enzymatic activity in the indicated lung cancer models, as assessed by immunoblotting and activity assays
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from DHODH-Mediated Suppression of Ferroptosis Supports Radioresistance and Represents a Therapeutic Vulnerability in Lung Cancer
Radiation increases DHODH expression and enzymatic activity in the indicated lung cancer models, as assessed by immunoblotting and activity assays
- Open Access
- 30 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis
Genetic heterogeneity contributes to the variable therapeutic responses in cancers. Frequent SPOP mutations and recurrent CHD1 deletions define distinct molecular subtypes of prostate cancer (PCa) with differential responses to anti-androgen therapy. Ferroptosis, an iron-dependent cell death mechanism driven by lipid peroxidation, has emerged as a promising anticancer strategy. Here, we identify SPOP mutations and CHD1 deletion as key genetic determinants of ferroptosis susceptibility in PCa. Using genetically engineered human and murine models, we show that SPOP mutations enhance, whereas CHD1 deletion impairs, the efficacy of ferroptosis inducers targeting GPX4. Mechanistically, SPOP and CHD1 exert opposing effects on ferroptosis by antagonistically regulating the MYC–ACSL4 axis. Furthermore, we demonstrate that targeting cholesterol metabolism with cholesterol-lowering agents restores ACSL4 expression and re-sensitizes SPOP/CHD1 co-deficient tumors to ferroptosis-inducing therapy. Our findings establish SPOP/CHD1 as upstream genetic regulators of ferroptosis and provide biomarker-driven combinatorial strategies to enhance ferroptosis-based therapy in men with advanced PCa.
- 30 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDivergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis
Genetic heterogeneity contributes to the variable therapeutic responses in cancers. Frequent SPOP mutations and recurrent CHD1 deletions define distinct molecular subtypes of prostate cancer (PCa) with differential responses to anti-androgen therapy. Ferroptosis, an iron-dependent cell death mechanism driven by lipid peroxidation, has emerged as a promising anticancer strategy. Here, we identify SPOP mutations and CHD1 deletion as key genetic determinants of ferroptosis susceptibility in PCa. Using genetically engineered human and murine models, we show that SPOP mutations enhance, whereas CHD1 deletion impairs, the efficacy of ferroptosis inducers targeting GPX4. Mechanistically, SPOP and CHD1 exert opposing effects on ferroptosis by antagonistically regulating the MYC–ACSL4 axis. Furthermore, we demonstrate that targeting cholesterol metabolism with cholesterol-lowering agents restores ACSL4 expression and re-sensitizes SPOP/CHD1 co-deficient tumors to ferroptosis-inducing therapy. Our findings establish SPOP/CHD1 as upstream genetic regulators of ferroptosis and provide biomarker-driven combinatorial strategies to enhance ferroptosis-based therapy in men with advanced PCa.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S1 shows relative IC50 of RSL3, ML210, JKE-1674, or ML162 in the indicated cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Table S1 shows relative IC50 of RSL3, ML210, JKE-1674, or ML162 in the indicated cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S7 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Figure S1 shows that BRCA1 deficiency promotes GPX4i–induced ferroptosis. Supplementary Figure S2 shows that BRCA1 regulates GPX4 through the BRCT domain. Supplementary Figure S3 shows that BRCA1 deficiency suppresses erastin-induced ferroptosis via interference with VDAC3 transcription and mitochondrial lipid peroxidation.Supplementary Figure S4 shows that PARPi synergize with GPX4i in BRCA1-deficient cancers via ferroptosis. Supplementary Figure S5 shows that PARPi combined with GPX4i in BRCA1-mutant/deficient or homologous-recombination-restored cells or tumors. Supplementary Figure S6 shows that NCOA4-mediated ferritinophagy coupled with defective GPX4 induction contributes to the synergy of PARPi and GPX4i in BRCA1-deficient cancer cells. Supplementary Figure S7 shows that GPX4i overcome resistance to PARPi in BRCA1-mutant tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S7 from BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers
Supplementary Figure S1 shows that BRCA1 deficiency promotes GPX4i–induced ferroptosis. Supplementary Figure S2 shows that BRCA1 regulates GPX4 through the BRCT domain. Supplementary Figure S3 shows that BRCA1 deficiency suppresses erastin-induced ferroptosis via interference with VDAC3 transcription and mitochondrial lipid peroxidation.Supplementary Figure S4 shows that PARPi synergize with GPX4i in BRCA1-deficient cancers via ferroptosis. Supplementary Figure S5 shows that PARPi combined with GPX4i in BRCA1-mutant/deficient or homologous-recombination-restored cells or tumors. Supplementary Figure S6 shows that NCOA4-mediated ferritinophagy coupled with defective GPX4 induction contributes to the synergy of PARPi and GPX4i in BRCA1-deficient cancer cells. Supplementary Figure S7 shows that GPX4i overcome resistance to PARPi in BRCA1-mutant tumors.